MiMedx Group Inc MDXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDXG is a good fit for your portfolio.
News
-
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
-
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
-
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
-
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
-
MIMEDX to Participate in Upcoming Investor Conferences
-
MIMEDX Announces First Quarter 2024 Operating and Financial Results
-
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit
-
Stocks to Watch: MiMedx Group, Nokia
Trading Information
- Previous Close Price
- $7.71
- Day Range
- $7.63–7.85
- 52-Week Range
- $5.57–9.27
- Bid/Ask
- $7.50 / $8.06
- Market Cap
- $1.15 Bil
- Volume/Avg
- 628,757 / 722,475
Key Statistics
- Price/Earnings (Normalized)
- 38.88
- Price/Sales
- 3.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.19%
Company Profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 895
- Website
- https://www.mimedx.com
Comparables
Valuation
Metric
|
MDXG
|
ATEC
|
RXST
|
---|---|---|---|
Price/Earnings (Normalized) | 38.88 | — | — |
Price/Book Value | 7.35 | 40.46 | 10.09 |
Price/Sales | 3.59 | 2.75 | 15.74 |
Price/Cash Flow | 16.92 | — | — |
Price/Earnings
MDXG
ATEC
RXST
Financial Strength
Metric
|
MDXG
|
ATEC
|
RXST
|
---|---|---|---|
Quick Ratio | 2.50 | 1.37 | 8.02 |
Current Ratio | 3.29 | 2.39 | 9.20 |
Interest Coverage | 8.24 | −9.60 | −27.34 |
Quick Ratio
MDXG
ATEC
RXST
Profitability
Metric
|
MDXG
|
ATEC
|
RXST
|
---|---|---|---|
Return on Assets (Normalized) | 50.04% | −9.36% | −13.53% |
Return on Equity (Normalized) | 184.85% | — | −16.23% |
Return on Invested Capital (Normalized) | 108.26% | −9.08% | −17.05% |
Return on Assets
MDXG
ATEC
RXST
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Sdrpzpkkl | Zwn | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Zybrfxmtj | Fnswnq | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Cqwqhthm | Jksgds | $118.7 Bil | |||
Moderna Inc
MRNA
| Wbkqdvtq | Ytknn | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Ymdvnkm | Pmqsqdh | $29.7 Bil | |||
argenx SE ADR
ARGX
| Rngfqvcs | Tlkwt | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Mhmlxlm | Gplyb | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Tngwlwzz | Hrfxq | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Lhqqkmfj | Sxvw | $15.0 Bil | |||
Incyte Corp
INCY
| Txmmdwwfg | Hwzvcy | $13.5 Bil |